A Mixed Probiotic/Prebiotic Intervention (MBR 01) for the Management of Diarrhea During Abemaciclib Treatment of Early Breast Cancer: A Single Center Prospective Case Control Pilot Study

BackgroundAdjuvant abemaciclib+endocrine therapy (ET) improves long-term outcomes in high-risk, hormone receptor-positive (HR+)/HER2-negative early breast cancer (eBC). However, treatment is frequently complicated by diarrhea, affecting adherence and quality of life (QoL). Increasing evidence suggests that abemaciclib-induced gastrointestinal toxicity may involve gut microbiota alterations. We conducted a prospective case-control pilot study evaluating the efficacy of MBR-01, a standardized prebiotic/probiotic formulation, in mitigating abemaciclib-induced diarrhea. MethodsWe enrolled 20 patients with high-risk HR+/HER2-negative eBC considered unfit for adjuvant chemotherapy. Patients received abemaciclib+letrozole (control, n=10) or abemaciclib+letrozole+MBR-01 (experimental, n=10). The primary endpoint was the incidence and severity of diarrhea; secondary endpoints included treatment adherence, QoL assessments and exploratory baseline/week-12 microbiota characterization according to treatment arm. Trial registration number: ISRCTN11948182. ResultsDiarrhea occurred in all patients. In the control group, diarrhea was predominantly grade 1 (50%) or grade 2 (40%), with one grade 3 event (10%). In the MBR-01 group, diarrhea frequency and severity were reduced by [~]70% at the end of week-12; 80% of patients experienced only grade 1 diarrhea or none by week-12, and no grade [≥]3 events. Dose modification was only required in one control. Alpha-diversity and depletion of F.prausnitzii were associated with earlier diarrhea onset and longer duration; enrichment in E.coli correlated with higher grade events. MBR-01 supplementation seemed to preserve microbial diversity and limited E.coli expansion. QoL was significantly improved with MBR-01. ConclusionMBR-01 may effectively mitigate abemaciclib-induced diarrhea, likely through the achievement of stabilization of gut microbiota composition. Larger prospective studies are warranted to validate these preliminary findings. HighlightsO_LIMBR-01, a prebiotic/probiotic, was given to reduce abemaciclib-induced diarrhea. C_LIO_LIMBR-01 reduced diarrhea by [~]70%, most patients had G0-1, one G [≥]3 at week 12. C_LIO_LIMBR-01 patients keep abemaciclib drug dose; 10% of controls required reduction. C_LIO_LIMBR-01 halved stool frequency and improved quality of life. C_LIO_LIMBR-01 preserved gut diversity, maintaining F. prausnitzii and limiting E. coli. C_LI